InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
4,967.23
(
-0.88%
)
US TECH 100
16,570.00
(
-2.16%
)
Dow Jones
37,986.40
(
0.56%
)
Brent Oil
86.63
(
0.24%
)
Bitcoin
64,355.66
(
1.33%
)
Post# of 38376
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

JokersWild12

Send PM Follow Ignore
Followers 10
Posts 529
Boards Moderated 0
Alias Born 12/15/2011

JokersWild12

Re: ronrooster post# 38023

Thursday, 03/02/2017 11:09:14 AM

Thursday, March 02, 2017 11:09:14 AM

Post# of 38376
Sweet news. They are VERY optimistic about NR2F6 for human(RGBP) and animal(ENTB) use and see high value with it and expect large company interest.

Nice to see the potential valuation for human immune-oncology deals for development biotechs that can exceed $1 billion+. They have potential beyond that with treating auto-immune disease meaning more $$$ in the valuation. Both of which apply to ENTB. NR2F6 success translates to $$$$ for ENTB.

They also mentioned they have been approached by numerous companies already. Obviously they believe that the value can be increased multi-fold with further optimization of NR2F6 which they plan on.

2017. ENTB low float. $$$$. All IMO.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up